Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Auguet, Teresa ^a,b   Berlanga, Alba ^a   Guiu Jurado, Esther ^a   Terra, Ximena ^a   Martinez, Salomé ^b   Aguilar, Carmen ^a   Filiu, Elisa ^b   Alibalic, Ajla ^b   Sabench, Fàtima ^c   Hernández, Mercé ^c   Del Castillo, Daniel ^c   Richart, Cristóbal ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE 1; ADIPONECTIN; BINDING PROTEIN; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; CD36 ANTIGEN; FARNESOID X RECEPTOR; FATTY ACID BINDING PROTEIN 4; FATTY ACID SYNTHASE; INTERLEUKIN 6; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CNR2 PROTEIN, HUMAN; FATTY ACID; MESSENGER RNA;

ADULT; ARTICLE; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; STEATOSIS; BIOSYNTHESIS; COHORT ANALYSIS; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ADIPOKINES; ADULT; BIOLOGICAL TRANSPORT; COHORT STUDIES; FATTY ACIDS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; OXIDATION-REDUCTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER;

EID: 84901251442     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/502542     Document Type: Article

References (38)

1. Harrison S. A., Diehl A. M., Fat and the liver-a molecular overview. Seminars in Gastrointestinal Disease 2002 13 1 3 16 2-s2.0-0036211591 (Pubitemid 34262947)
2. Clark J. M., Brancati F. L., Diehl A. M., Nonalcoholic fatty liver disease. Gastroenterology 2002 122 6 1649 1657 2-s2.0-0036090972 (Pubitemid 34533559)
3. Angulo P., Medical progress: nonalcoholic fatty liver disease. The New England Journal of Medicine 2002 346 16 1221 1231 2-s2.0-0037129380 10.1056/NEJMra011775 (Pubitemid 34984585)
4. Vernon G., Baranova A., Younossi Z. M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics 2011 34 3 274 285 2-s2.0-79960029926 10.1111/j.1365-2036.2011. 04724.x
5. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., Rizzetto M., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37 4 917 923 2-s2.0-0037382786 10.1053/jhep.2003.50161 (Pubitemid 36397405)
6. Ong J. P., Younossi Z. M., Epidemiology and natural history of NAFLD and NASH. Clinics in Liver Disease 2007 11 1 1 16 2-s2.0-34249668818 10.1016/j.cld.2007.02.009 (Pubitemid 46829973)
7. Tilg H., Moschen A. R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010 52 5 1836 1846 2-s2.0-78049522194 10.1002/hep.24001
8. Day C. P., Clinical spectrum and therapy of non-alcoholic steatohepatitis. Digestive Disease 2012 30 supplement 1 69 73 10.1159/000341128
9. Postic C., Girard J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Journal of Clinical Investigation 2008 118 3 829 838 2-s2.0-40549135297 10.1172/JCI34275 (Pubitemid 351364588)
10. Lima-Cabello E., García-Mediavilla M. V., Miquilena-Colina M. E., Vargas-Castrillón J., Lozano-Rodríguez T., Fernández- Bermejo M., Olcoz J. L., González-Gallego J., García-Monzón C., Sánchez-Campos S., Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clinical Science 2011 120 6 239 250 2-s2.0-79251639639 10.1042/CS20100387
11. Nakamuta M., Fujino T., Yada R., Yada M., Yasutake K., Yoshimoto T., Harada N., Higuchi N., Kato M., Kohjima M., Taketomi A., Maehara Y., Nakashima M., Kotoh K., Enjoji M., Impact of cholesterol metabolism and the LXR α -SREBP-1c pathway on nonalcoholic fatty liver disease. International Journal of Molecular Medicine 2009 23 5 603 608 2-s2.0-67649429268 10.3892/ijmm-00000170
12. Kohjima M., Enjoji M., Higuchi N., Kato M., Kotoh K., Yoshimoto T., Fujino T., Yada M., Yada R., Harada N., Takayanagi R., Nakamuta M., Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. International Journal of Molecular Medicine 2007 20 3 351 358 2-s2.0-35148881190
13. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertáler L., Wang L., Kunos G., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. Journal of Clinical Investigation 2005 115 5 1298 1305 2-s2.0-20944436157 10.1172/JCI200523057 (Pubitemid 40629049)
14. Jeong W.-I., Osei-Hyiaman D., Park O., Liu J., Bátkai S., Mukhopadhyay P., Horiguchi N., Harvey-White J., Marsicano G., Lutz B., Gao B., Kunos G., Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metabolism 2008 7 3 227 235 2-s2.0-38649114788 10.1016/j.cmet.2007.12.007 (Pubitemid 351285525)
15. di Marzo V., Piscitelli F., Mechoulam R., Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handbook of Experimental Pharmacology 2011 2011 75 104 2-s2.0-79955632246 10.1007/978-3-642-17214-4-4
16. Pacher P., Mechoulam R., Is lipid signaling through cannabinoid 2 receptors part of a protective system? Progress in Lipid Research 2011 50 2 193 211 2-s2.0-79952198989 10.1016/j.plipres.2011.01.001
17. Pacher P., Bátkai S., Kunos G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 2006 58 3 389 462 2-s2.0-33748703859 10.1124/pr.58.3.2 (Pubitemid 44394908)
18. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A. C. E., Pasquali R., Lutz B., Stalla G. K., Pagotto U., The endogenous cennabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation 2003 112 3 423 431 2-s2.0-0041886785 10.1172/JCI200317725 (Pubitemid 38063771)
19. Mallat A., Teixeira-Clerc F., Lotersztajn S., Cannabinoid signaling and liver therapeutics. Journal of Hepatology 2013 59 4 891 896 10.1016/j.jhep.2013. 03.032
20. Mendez-Sanchez N., Zamora-Valdes D., Pichardo-Bahena R., Barredo-Prieto B., Ponciano-Rodriguez G., Bermejo-Martínez L., Chavez-Tapia N. C., Baptista-González H. A., Uribe M., Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver International 2007 27 2 215 219 2-s2.0-34247579754 10.1111/j.1478-3231.2006.01401.x (Pubitemid 46680725)
21. Kleiner D. E., Brunt E. M., van Natta M., Behling C., Contos M. J., Cummings O. W., Ferrell L. D., Liu Y.-C., Torbenson M. S., Unalp-Arida A., Yeh M., McCullough A. J., Sanyal A. J., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 6 1313 1321 2-s2.0-20044374023 10.1002/hep.20701 (Pubitemid 40770284)
22. Brunt E. M., Janney C. G., di Bisceglie A. M., Neuschwander-Tetri B. A., Bacon B. R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. American Journal of Gastroenterology 1999 94 9 2467 2474 2-s2.0-0033200054 10.1111/j.1572-0241.1999.01377.x (Pubitemid 29420675)
23. Terra X., Auguet T., Broch M., Retinol binding protein-4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women. Obesity 2013 21 1 170 177 10.1002/oby.20233
24. Tam J., Vemuri V. K., Liu J., Bátkai S., Mukhopadhyay B., Godlewski G., Osei-Hyiaman D., Ohnuma S., Ambudkar S. V., Pickel J., Makriyannis A., Kunos G., Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. Journal of Clinical Investigation 2010 120 10 2953 2966 2-s2.0-77957833090 10.1172/JCI42551C1
25. Gary-Bobo M., Elachouri G., Gallas J. F., Janiak P., Marini P., Ravinet-Trillou C., Chabbert M., Cruccioli N., Pfersdorff C., Roque C., Arnone M., Croci T., Soubrié P., Oury-Donat F., Maffrand J. P., Scatton B., Lacheretz F., Le Fur G., Herbert J. M., Bensaid M., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats. Hepatology 2007 46 1 122 129 2-s2.0-34547423962 10.1002/hep.21641 (Pubitemid 47171928)
26. Jourdan T., Djaouti L., Demizieux L., Gresti J., Vergès B., Degrace P., CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010 59 4 926 934 2-s2.0-77951184370 10.2337/db09-1482
27. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.-I., Bátkai S., Marsicano G., Lutz B., Buettner C., Kunos G., Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Journal of Clinical Investigation 2008 118 9 3160 3169 2-s2.0-51349153318 10.1172/JCI34827
28. Mandard S., Müller M., Kersten S., Peroxisome proliferator-activated receptor α target genes. Cellular and Molecular Life Sciences 2004 61 4 393 416 2-s2.0-1542283630 10.1007/s00018-003-3216-3 (Pubitemid 38316578)
29. 2+ and AMPK/SIRT1. Nature 2010 464 7293 1313 1319 2-s2.0-77951872309 10.1038/nature08991
30. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease. Nature 2000 405 6785 421 424 2-s2.0-0034713444 10.1038/35013000 (Pubitemid 30367411)
31. Okada-Iwabu M., Yamauchi T., Iwabu M., A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013 503 493 499 10.1038/nature12656
32. Louvet A., Teixeira-Clerc F., Chobert M.-N., Deveaux V., Pavoine C., Zimmer A., Pecker F., Mallat A., Lotersztajn S., Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 2011 54 4 1217 1226 2-s2.0-80053314254 10.1002/hep.24524
33. Lotersztajn S., Teixeira-Clerc F., Julien B., Deveaux V., Ichigotani Y., Manin S., Tran-Van-Nhieu J., Karsak M., Zimmer A., Mallat A., CB2 receptors as new therapeutic targets for liver diseases. British Journal of Pharmacology 2008 153 2 286 289 2-s2.0-38349095862 10.1038/sj.bjp.0707511
34. Agudo J., Martin M., Roca C., Molas M., Bura A. S., Zimmer A., Bosch F., Maldonado R., Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010 53 12 2629 2640 2-s2.0-78649331179 10.1007/s00125-010-1894-6
35. Myoung S. H., Sun Y. P., Shinzawa K., Kim S., Kun W. C., Lee J.-H., Choon H. K., Lee K.-W., Lee J.-H., Cheol K. P., Woo J. C., Jae S. H., Yan J.-J., Song D.-K., Tsujimoto Y., Lee M.-S., Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. Journal of Lipid Research 2008 49 1 84 97 2-s2.0-38049186666 10.1194/jlr.M700184-JLR200
36. Jiang H.-Y., Wek S. A., McGrath B. C., Scheuner D., Kaufman R. J., Cavener D. R., Wek R. C., Phosphorylation of the α subunit of eukaryotic initiation factor 2 is required for activation of NF- B in response to diverse cellular stresses. Molecular and Cellular Biology 2003 23 16 5651 5663 2-s2.0-0043133837 10.1128/MCB.23.16.5651-5663.2003 (Pubitemid 36951330)
37. Seo J., Fortuno E. S. III, Jae M. S., Stenesen D., Tang W., Parks E. J., Adams C. M., Townes T., Graff J. M., Atf4 regulates obesity, glucose homeostasis, and energy expenditure. Diabetes 2009 58 11 2565 2573 2-s2.0-70350539531 10.2337/db09-0335
38. Deveaux V., Cadoudal T., Ichigotani Y., Teixeira-Clerc F., Louvet A., Manin S., Nhieu J. T.-V., Belot M. P., Zimmer A., Even P., Cani P. D., Knauf C., Burcelin R., Bertola A., Le Marchand-Brustel Y., Gual P., Mallat A., Lotersztajn S., Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE 2009 4 6 2-s2.0-67649159879 10.1371/journal.pone.0005844 e5844